A Phase 2 Multicenter Study of High Dose Chemotherapy With Autologous Stem Cell Transplant Followed by Maintenance Therapy With Romidepsin for the Treatment of T Cell Non-Hodgkin Lymphoma

Trial Profile

A Phase 2 Multicenter Study of High Dose Chemotherapy With Autologous Stem Cell Transplant Followed by Maintenance Therapy With Romidepsin for the Treatment of T Cell Non-Hodgkin Lymphoma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 26 May 2017

At a glance

  • Drugs Romidepsin (Primary)
  • Indications T cell lymphoma
  • Focus Therapeutic Use
  • Sponsors Memorial Sloan-Kettering Cancer Center
  • Most Recent Events

    • 05 Jan 2017 Planned End Date changed from 1 Jul 2017 to 1 Jul 2018.
    • 05 Jan 2017 Planned primary completion date changed from 1 Jul 2017 to 1 Jul 2018.
    • 31 Jul 2013 New source identified and integrated: Memorial Sloan-Kettering Cancer Center record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top